A unique PRAD risk model based on the two-factor combination of ZNF330 and PITPNM3 was developed, which not only predicts survival but also predicts the immunotherapy responses of PRAD patients of varying risk. This evidence concerns the gene PITPNM3 and prostate adenocarcinoma.